COMP <GO>
TLX vs ELVN // EV/EBITDA & P/E VALUATION
Telix Pharmaceuticals Limited (NASDAQ) VS. Enliven Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TLX 0
— ELVN 2
■ METRIC PARITY
LAST: $9.51 (+2.70%) • MKT CAP: $3.22B
valuation
—
LAST: $45.08 (+0.67%) • MKT CAP: $3.30B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TLX VS. ELVN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TLX | ELVN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -26.20% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.13% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.2 | 51.0 | -15.82 | ELVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.22B | $3.30B | -$81.3M | ELVN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TLX REV | ELVN REV | TLX GROSS % | ELVN GROSS % | TLX FCF | ELVN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$70.3M |
| FY 2024 | — | $0 | — | — | — | -$73.2M |
| FY 2023 | — | $0 | — | — | — | -$61.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TLX // BETA —
ELVN // BETA —